SCHEMBL3130447

SCHEMBL3130447

O=CCNCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
ADH1B P00325 1/20 0.58
ADH1C P00326 1/20 0.58
ADH1A P07327 1/20 0.58
ADH7 P40394 1/20 0.58
DPP7 Q9UHL4 1/20 0.55
MAOA P21397 1/20 0.52
CHRM2 P08172 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
SIGMAR1 Q99720 3/20 0.47
CA2 P00918 2/20 0.46
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
CA14 Q9ULX7 1/20 0.46
IDO1 P14902 2/20 0.46
THRB P10828 1/20 0.46
CA1 P00915 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15607673 0.85 MEN1 (0.64) MEN1KMT2ATDP1ADH1BADH1C
SCHEMBL4865476 0.81 SMN1; SMN2 (0.43) MEN1KMT2ATDP1ADH1BADH1C
SCHEMBL27625443 0.79 MEN1 (0.56) MEN1KMT2ATDP1ADH1BADH1C
SCHEMBL27686314 0.79 MEN1 (0.56) MEN1KMT2ATDP1ADH1BADH1C
SCHEMBL681149 0.79 MEN1 (0.56) MEN1KMT2ATDP1ADH1BADH1C
SCHEMBL1654 0.79 MEN1 (0.78) MEN1KMT2ATDP1ADH1BADH1C
Benzene SCHEMBL11697595 0.79 MEN1 (0.78) MEN1KMT2ATDP1ADH1BADH1C
SCHEMBL5799878 0.79 MEN1 (0.78) MEN1KMT2ATDP1ADH1BADH1C
SCHEMBL14269470 0.77 LMNA (0.55) MEN1KMT2ADPP7CHRM2CA2
SCHEMBL21414853 0.77 CHRM2 (0.53) MEN1KMT2ATDP1CHRM2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012164476-A1 NEW TRICYCLIC COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS LIGANDS OF THE BETA AMYLOID PEPTIDES UNIVERSITÀ DEGLI STUDIO DI MILANO - BICOCCA (IT) 2012-12-06 WO claimed
CN-102015993-A Encapsulated benefit agent UNILEVER PLC 2011-04-13 CN claimed
EP-2044083-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2009-04-08 EP claimed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US claimed
WO-2008008907-A2 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 WO claimed
WO-2008008912-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 WO claimed
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 US claimed
JP-11276808-A None JP disclosed
US-20240240062-A1 (METH)ACRYLATE-BASED TWO-PART ADHESIVE COMPOSITION HENKEL AG & CO KGAA (DE) 2024-07-18 US disclosed
CN-118043422-A Two-part adhesive compositions based on (meth) acrylic esters 汉高股份有限及两合公司 2024-05-14 CN disclosed
WO-2023106896-A1 NOVEL ADIPONECTIN-DERIVED PEPTOID DERIVATIVE AND USE THEREOF 서울대학교병원 2023-06-15 WO disclosed
WO-2023050111-A1 (METH) ACRYLATE-BASED TWO-PART ADHESIVE COMPOSITION HENKEL AG & CO. KGAA (DE) 2023-04-06 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20030232391-A1 Identification of kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2003-12-18 US disclosed
WO-2003087204-A1 CURABLE FOAM ELASTOMERIC COMPOSITIONS HENKEL CORPORATION (US) 2003-10-23 WO disclosed
EP-1337853-A2 AN EXTENDED TETHERING APPROACH FOR RAPID IDENTIFICATION OF LIGANDS Sunesis Pharmaceuticals, Inc. (US) 2003-08-27 EP disclosed
US-20020150947-A1 Extended tethering approach for rapid identification of ligands SUNESIS PHARMACEUTICALS, INC. 2002-10-17 US disclosed
WO-2002042773-A2 AN EXTENDED TETHERING APPROACH FOR RAPID IDENTIFICATION OF LIGANDS SUNESIS PHARMACEUTICALS, INC. (US) 2002-05-30 WO disclosed
JP-H11276808-A DEHYDRATING AGENT FOR FILTER PRESS AND DEHYDRATION HYMO CORP 1999-10-12 JP disclosed
EP-0178381-A2 Phenylacetamides as anti-allergy, anti-asthma and anti-inflammatory agents USV PHARMACEUTICAL CORPORATION (US) 1986-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses HAVCR2, ZC3HAV1, SARS1 MEN1 4103/4885KMT2A 2460/4885TDP1 2016/4885
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 MEN1 4834/4885KMT2A 4254/4885TDP1 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.